

## Seventh Meeting Pharma-Biotech: THERAPEUTIC AREA ON ONCOLOGY (Within the framework of BioSpain 2012: Bilbao)

### AGENDA

09:00 09:15	Registration	
09:15 09:30	Welcome session	Farmaindustria
09:30 10:00	IKH02: Inhibitor of HDAC as monotherapy for liver cancer. The preclinical regulatory validation phase has been finished.	Eider San Sebastián IKERCHEM, SL
10:00 10:30	New drugs against invasive tumors in breast and pancreas, from the human protein Cystatin-C.	Myriam Fabr�e ONCOMATRIX, SL
10:30 11:00	APDD01: New drug for oral administration that can focus on several tumors. The preclinical regulatory validation phase has been started.	Sim�o Swarch ARGON PHARMA, SL
11:00 11:30	Coffee break	
11:30 12:00	EC 70124: Inhibitor of NF-kB route, which attacks the tumor stem cells. The preclinical regulatory validation phase has been started.	Francisco Mor�s ENTRECHEM, SL
12:00 12:30	Ab anti-ephrinB2: New therapy looked at inhibiting angiogenesis. Transfer from research done in the Spanish National Cancer Research Centre.	Dami� Tormo BIONCOTECH, SL
12:30 13:00	LK1: Selective antagonist exclusive of Integrin avb3. Transfer from research done in Leitaf Technological Center.	Francesc Mitjans LIKERA BIOMED, SA
13:00 13:15	Closing session	Farmaindustria

NOTA: All presentations will be made in Spanish, although the written documentation will be available in English

Venue address: Bilbao Exhibition Centre (Ronda de Azkue 1. 48902 Ansio-Barakaldo)

Date: Friday, 21st September 2012